SGLT2 inhibitors: A groundbreaking class of cardiovascular drugs, but who benefits most?

被引：0
|
作者：
Koufakis, Theocharis [1 ]
Popovic, Djordje S. [2 ,3 ]
Maltese, Giuseppe [4 ,5 ]
Papanas, Nikolaos [6 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippokration Gen Hosp, Propedeut Dept Internal Med 2, Thessaloniki 54642, Greece
[2] Clin Ctr Vojvodina, Clin Endocrinol Diabet & Metab Disorders, Novi Sad, Serbia
[3] Univ Novi Sad, Med Fac, Novi Sad, Serbia
[4] Epsom & St Helier Univ Hosp, Dept Diabet & Endocrinol, Sutton SM5 1AA, Surrey, England
[5] Kings Coll London, Fac Life Sci & Med, Cardiovasc Div, Unit Metab Med, London WC2R 2LS, England
[6] Democritus Univ Thrace, Univ Hosp Alexandroupolis, Diabet Ctr, Dept Internal Med 2, Alexandroupolis, Greece
来源：
INTERNATIONAL JOURNAL OF CARDIOLOGY | 2024年 / 412卷
关键词：
SGLT2; inhibitors; Heart failure; Myocardial infarction; Nt-proBNP;
D O I：
10.1016/j.ijcard.2024.132326
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Extrarenal Benefits of SGLT2 Inhibitors in the Treatment of Cardiomyopathies
    Yerra, Veera Ganesh
    Connelly, Kim A.
    PHYSIOLOGY, 2024, 39 (06) : 412 - 434
  • [22] SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus
    d'Emden, Michael
    Amerena, John
    Deed, Gary
    Pollock, Carol
    Cooper, Mark E.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 136 : 23 - 31
  • [23] SGLT2 inhibitors: cardiorenal metabolic drugs for the ages
    Defronzo, Ralph A.
    JOURNAL OF CLINICAL INVESTIGATION, 2024, 134 (05):
  • [24] A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
    Sano, Motoaki
    JOURNAL OF CARDIOLOGY, 2018, 71 (5-6) : 471 - 476
  • [25] Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?
    J. A. Lovshin
    R. E. Gilbert
    Current Hypertension Reports, 2015, 17
  • [26] Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?
    Lovshin, J. A.
    Gilbert, R. E.
    CURRENT HYPERTENSION REPORTS, 2015, 17 (06) : 1 - 9
  • [27] SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
    Bell, Robert M.
    Yellon, Derek M.
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (06): : 435 - 437
  • [28] SGLT2 inhibitors for primary prevention of cardiovascular events
    Raz, Itamar
    Cernea, Simona
    Cahn, Avivit
    JOURNAL OF DIABETES, 2020, 12 (01) : 5 - 7
  • [29] Prescription of SGLT2 inhibitors in hospitalized cardiovascular patients
    Hofer, F.
    Zelniker, T. A.
    Koller, L.
    Kazem, N.
    Schweitzer, R.
    Sulzgruber, P.
    Niessner, A.
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : S247 - S248
  • [30] Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
    Vallon, Volker
    Verma, Subodh
    ANNUAL REVIEW OF PHYSIOLOGY, VOL 83, 2021, 83 : 503 - 528
12345